Alnylam Pharmaceuticals (ALNY) Net Income towards Common Stockholders Growth (3y) (2012 - 2026)
Alnylam Pharmaceuticals (ALNY) Net Income towards Common Stockholders Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 144.84% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 47.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47.10% |
| Dec 31, 2025 | 36.40% |
| Sep 30, 2025 | 39.61% |
| Jun 30, 2025 | 37.95% |
| Mar 31, 2025 | 57.65% |
| Dec 31, 2024 | 31.31% |
| Sep 30, 2024 | 18.29% |
| Jun 30, 2024 | 55.34% |
| Mar 31, 2024 | 30.95% |
| Dec 31, 2023 | 17.28% |
| Sep 30, 2023 | 37.21% |
| Jun 30, 2023 | -15.48% |
| Mar 31, 2023 | 1.51% |
| Dec 31, 2022 | 9.09% |
| Sep 30, 2022 | -24.86% |
| Jun 30, 2022 | -8.12% |
| Mar 31, 2022 | -9.73% |
| Dec 31, 2021 | -6.92% |
| Sep 30, 2021 | 5.88% |
| Jun 30, 2021 | -5.04% |